{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:15:43Z","timestamp":1790342143623,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00415-025-13039-7","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T21:32:10Z","timestamp":1743197530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring autoantigens in autoimmune limbic encephalitis using phage immunoprecipitation sequencing"],"prefix":"10.1007","volume":"272","author":[{"given":"Haidara","family":"Kherbek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen K.","family":"Paramasivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carley","family":"Karsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smathorn","family":"Thakolwiboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reghann G.","family":"LaFrance-Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaniolky","family":"Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-9045","authenticated-orcid":false,"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"1","key":"13039_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ana.25131","volume":"83","author":"D Dubey","year":"2018","unstructured":"Dubey D et al (2018) Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 83(1):166\u2013177","journal-title":"Ann Neurol"},{"issue":"4","key":"13039_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391\u2013404","journal-title":"Lancet Neurol"},{"issue":"3","key":"13039_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200151","volume":"13","author":"E Orozco","year":"2023","unstructured":"Orozco E et al (2023) Autoimmune encephalitis criteria in clinical practice. Neurol Clin Pract 13(3):e200151","journal-title":"Neurol Clin Pract"},{"key":"13039_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","author":"F Graus","year":"2021","unstructured":"Graus F et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"13039_CR5","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/clinchem\/hvaa254","volume":"66","author":"A Budhram","year":"2020","unstructured":"Budhram A et al (2020) Neural antibody testing in patients with suspected autoimmune encephalitis. Clin Chem 66(12):1496\u20131509","journal-title":"Clin Chem"},{"issue":"1","key":"13039_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/ana.26943","volume":"96","author":"M Gilligan","year":"2024","unstructured":"Gilligan M et al (2024) Paraneoplastic calmodulin kinase-like vesicle-associated protein (CAMKV) autoimmune encephalitis. Ann Neurol 96(1):21\u201333","journal-title":"Ann Neurol"},{"issue":"8","key":"13039_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/jamaneurol.2022.1357","volume":"79","author":"D Dubey","year":"2022","unstructured":"Dubey D et al (2022) Identification of caveolae-associated protein 4 autoantibodies as a biomarker of immune-mediated rippling muscle disease in adults. JAMA Neurol 79(8):808\u2013816","journal-title":"JAMA Neurol"},{"issue":"9","key":"13039_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/ph14090836","volume":"14","author":"C Pr\u00edncipe","year":"2021","unstructured":"Pr\u00edncipe C et al (2021) LRP1B: a giant lost in cancer translation. Pharmaceuticals (Basel) 14(9):836","journal-title":"Pharmaceuticals (Basel)"},{"key":"13039_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577861","volume":"367","author":"I McKeon-Makki","year":"2022","unstructured":"McKeon-Makki I et al (2022) Adenylate kinase 5 (AK5) autoimmune encephalitis: clinical presentations and outcomes in three new patients. J Neuroimmunol 367:577861","journal-title":"J Neuroimmunol"},{"key":"13039_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.576975","volume":"334","author":"CI Bien","year":"2019","unstructured":"Bien CI et al (2019) Identification of adenylate kinase 5 antibodies during routine diagnostics in a tissue-based assay: three new cases and a review of the literature. J Neuroimmunol 334:576975","journal-title":"J Neuroimmunol"},{"issue":"6","key":"13039_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1212\/WNL.0000000000003586","volume":"88","author":"LD Do","year":"2017","unstructured":"Do LD et al (2017) Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. Neurology 88(6):514\u2013524","journal-title":"Neurology"},{"issue":"9","key":"13039_CR12","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1093\/brain\/awab153","volume":"144","author":"S Mu\u00f1iz-Castrillo","year":"2021","unstructured":"Mu\u00f1iz-Castrillo S et al (2021) Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain 144(9):2709\u20132721","journal-title":"Brain"},{"key":"13039_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jneuroim.2015.08.009","volume":"287","author":"AS Ng","year":"2015","unstructured":"Ng AS et al (2015) Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis. J Neuroimmunol 287:31\u201335","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"13039_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jneuroim.2007.03.015","volume":"186","author":"E T\u00fcz\u00fcn","year":"2007","unstructured":"T\u00fcz\u00fcn E et al (2007) Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. J Neuroimmunol 186(1\u20132):177\u2013180","journal-title":"J Neuroimmunol"},{"key":"13039_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001010","author":"A Vicino","year":"2021","unstructured":"Vicino A et al (2021) Anti-adenylate kinase 5 encephalitis with histologic evidence of CNS vasculitis. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001010","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"13039_CR16","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/j.1460-9568.2006.05172.x","volume":"24","author":"M Shamloo","year":"2006","unstructured":"Shamloo M et al (2006) Npas4, a novel helix-loop-helix PAS domain protein, is regulated in response to cerebral ischemia. Eur J Neurosci 24(10):2705\u20132720","journal-title":"Eur J Neurosci"},{"issue":"6","key":"13039_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/07853890600946500","volume":"38","author":"BS Pickard","year":"2006","unstructured":"Pickard BS et al (2006) The NPAS3 gene\u2013emerging evidence for a role in psychiatric illness. Ann Med 38(6):439\u2013448","journal-title":"Ann Med"},{"issue":"37","key":"13039_CR18","doi-asserted-by":"publisher","first-page":"13648","DOI":"10.1073\/pnas.0405310101","volume":"101","author":"C Erbel-Sieler","year":"2004","unstructured":"Erbel-Sieler C et al (2004) Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proc Natl Acad Sci U S A 101(37):13648\u201313653","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"13039_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1248\/bpb.32.999","volume":"32","author":"N Shimizu","year":"2009","unstructured":"Shimizu N et al (2009) Pax6-5a promotes neuronal differentiation of murine embryonic stem cells. Biol Pharm Bull 32(6):999\u20131003","journal-title":"Biol Pharm Bull"},{"issue":"12","key":"13039_CR20","doi-asserted-by":"publisher","first-page":"29011","DOI":"10.3390\/ijms161226144","volume":"16","author":"FC Choy","year":"2015","unstructured":"Choy FC et al (2015) The role of the neuroprotective factor Npas4 in cerebral ischemia. Int J Mol Sci 16(12):29011\u201329028","journal-title":"Int J Mol Sci"},{"issue":"5","key":"13039_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/ana.26050","volume":"89","author":"D Dubey","year":"2021","unstructured":"Dubey D et al (2021) Leucine zipper 4 autoantibody: a novel germ cell tumor and paraneoplastic biomarker. Ann Neurol 89(5):1001\u20131010","journal-title":"Ann Neurol"},{"issue":"Pt 7","key":"13039_CR22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/123.7.1481","volume":"123","author":"SH Gultekin","year":"2000","unstructured":"Gultekin SH et al (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123(Pt 7):1481\u20131494","journal-title":"Brain"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13039-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13039-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13039-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T10:09:23Z","timestamp":1744970963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13039-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["13039"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13039-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.K., N.K.P., S.D., C.K., S.T., A.M.K., R.L.C., V.L., and J.R.M. report no conflicts interest. S.J.P. reports receiving grants, personal fees paid to Mayo Clinic, and nonfinancial support from Alexion Pharmaceuticals, Inc. and MedImmune, Inc.\/Viela Bio; receiving personal fees from Genentech\/Roche, UCB, and Astellas, outside the submitted work; holding patent 8,889,102 (application 12\u2013678350) issued and patent 9,891,219B2 (application 12\u2013573942) issued. A.Z. has patent applications pending on CAMKV-IgG, PDE10A-IgG, and DACH1-IgG as biomarkers of paraneoplastic neurological autoimmunity and has received research funding from Genentech. A.M. reports research funding from National Institutes of Health (NIH: RO1NS126227, U01NS120901), patents issued for GFAP and MAP1B-IgGs and patents pending for CAMKV, PDE10A, Septins-5 and -7, and KLHL11-IgGs, and has consulted for Janssen and Roche pharmaceuticals, without personal compensation. M.G. has a patent pending for CAMKV-IgG. D.D. has consulted for UCB, Immunovant, Argenx, Arialys, and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He is a named inventor on filed patent that relates to KLHL11 as marker of autoimmunity and germ cell tumor. He has patents pending for LUZP4-IgG, cavin-4-IgG and SKOR2-IgG as markers of neurological autoimmunity. He has received funding from the DOD (CA210208, PR220430\u00a0&\u00a0AL240239), David J. Tomassoni ALS Research Grant Program and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The studies involving humans was approved by Mayo Clinic, Rochester, Minnesota (IRB#08\u2013006647). The study was conducted in accordance with the local legislation and institutional requirements. This research was carried out utilizing residual serum\/CSF samples received at Mayo Clinic Neuroimmunology laboratory for clinical neural autoantibody evaluation. Clinical information was collected from the managing physician for the purposes of autoantibody development or validation. The study carried out for identification and confirmation of the putative autoantibody was covered by IRB#08\u2013006647, in compliance with the applicable regulations for the protection of human subjects and with Mayo Clinic Institutional Policies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"292"}}